Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931974 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL4934783 | 0.95 | SLC6A3 (0.56) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL4934782 | 0.95 | SLC6A3 (0.56) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL14026975 | 0.89 | SLC6A3 (0.56) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL4226115 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL4226118 | 0.87 | SLC6A2 (0.49) | SLC6A2SLC6A3KDM4EALDH1A1HTT | |
| SCHEMBL4228506 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A3ALDH1A1OPRK1KCNH2 | |
| SCHEMBL4228503 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A3ALDH1A1OPRK1KCNH2 | |
| SCHEMBL4934168 | 0.83 | MAPK14 (0.56) | SLC6A2SLC6A3HTTSMN1; SMN2OPRK1 | |
| SCHEMBL4934170 | 0.83 | MAPK14 (0.56) | SLC6A2SLC6A3HTTSMN1; SMN2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | SLC6A2 231/4885SLC6A3 212/4885KDM4E 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.